Eton Pharmaceuticals, Inc. (ETON) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
ETON currently has 27.3M outstanding shares. with significant dilution risk as 25.7M authorized shares could dilute existing holders by 94.3%. The company has minimally diluted shareholders by 5.89% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 14, 2026 |
10-Q filing | 27.3M shares outstanding |
27M | 26M |
| Mar 19, 2026 |
10-K filing | 26.9M shares outstanding |
27M | 26M |
| Nov 06, 2025 |
10-Q filing | 26.9M shares outstanding |
27M | 26M |
| Aug 07, 2025 |
10-Q filing | 26.9M shares outstanding |
27M | 26M |
| May 13, 2025 |
10-Q filing | 26.9M shares outstanding |
27M | 26M |
| Mar 18, 2025 |
10-K filing | 25.9M shares outstanding |
26M | 27M |
| Dec 12, 2024 |
8-K filing: Eton Pharmaceuticals, Inc. entered into a Securities Purchase Agreement with an institutional investor to issue and sell 583,334 shares of common stock at $12.00 per share in a registered direct offering, with gross proceeds of approximately $7.0 million. ($7.0M proceeds) |
26M | 27M |
| Nov 12, 2024 |
10-Q filing | 25.8M shares outstanding |
26M | 27M |
| Oct 03, 2024 |
8-K filing: Eton Pharmaceuticals, Inc. entered into an Asset Purchase Agreement to acquire Increlex® from Ipsen Biopharmaceuticals, Inc. and amended its credit agreement with SWK Holdings, issuing a warrant for 289,736 shares of common stock contingent upon the closing of the acquisition. |
26M | 27M |
| Aug 08, 2024 |
10-Q filing | 25.7M shares outstanding |
26M | 27M |
| May 09, 2024 |
10-Q filing | 25.7M shares outstanding |
26M | 27M |
| Mar 14, 2024 |
10-K filing | 25.6M shares outstanding |
26M | 27M |
| Nov 09, 2023 |
10-Q filing | 25.7M shares outstanding |
26M | 27M |
| Aug 10, 2023 |
10-Q filing | 25.6M shares outstanding |
26M | 27M |
| May 11, 2023 |
10-Q filing | 25.5M shares outstanding |
26M | 27M |
| Apr 07, 2023 |
S-3 filing: The company is offering common stock, preferred stock, debt securities and subscription rights for a maximum aggregate offering price of $100,000,000. |
26M | 27M |
| Mar 16, 2023 |
10-K filing | 25.1M shares outstanding |
25M | 0 |
| Nov 10, 2022 |
10-Q filing | 25.4M shares outstanding |
25M | 0 |
| Aug 11, 2022 |
10-Q filing | 25.3M shares outstanding |
25M | 0 |
| May 12, 2022 |
10-Q filing | 25.3M shares outstanding |
25M | 0 |
| Mar 16, 2022 |
10-K filing | 24.6M shares outstanding |
25M | 0 |
| Nov 16, 2021 |
10-Q filing | 24.6M shares outstanding |
25M | 0 |
| Aug 16, 2021 |
10-Q filing | 25.2M shares outstanding |
25M | 0 |
| May 13, 2021 |
10-Q filing | 24.5M shares outstanding |
24M | 0 |
| Apr 13, 2021 |
8-K filing: Eton Pharmaceuticals, Inc. announced the closing of a public offering of 1,518,000 shares of its common stock by Harrow Health, Inc. at a price of $7.00 per share, resulting in gross proceeds of approximately $10.63 million to the Selling Stockholder. ($10.63M proceeds) |
18M | 0 |
| Apr 08, 2021 |
8-K filing: Harrow Health, Inc. sold 1,320,000 shares of Eton Pharmaceuticals, Inc. common stock at a price of $7.00 per share, with gross proceeds expected to be approximately $9.24 million before deducting underwriting discounts and other offering expenses. ($9.24M proceeds) |
18M | 0 |
| Mar 16, 2021 |
10-K filing | 17.9M shares outstanding |
18M | 6.5M |
| Nov 12, 2020 |
10-Q filing | 24.2M shares outstanding |
24M | 200K |
| Oct 16, 2020 |
8-K filing: Eton Pharmaceuticals, Inc. announced the closing of its offering of 3,220,000 shares of common stock at a public offering price of $7.00 per share. ($22.54M proceeds) |
21M | 3.5M |
| Oct 14, 2020 |
8-K filing: Eton Pharmaceuticals, Inc. entered into an underwriting agreement for a public offering of 2,800,000 shares of common stock at $7.00 per share, with an over-allotment option for an additional 420,000 shares. ($19.6M proceeds) |
21M | 3.5M |
| Aug 12, 2020 |
10-Q filing | 21.0M shares outstanding |
21M | 3.5M |
| Jul 31, 2020 |
S-3 filing: Resale of up to 3,500,000 shares of common stock by the selling stockholder, Harrow Health, Inc. |
21M | 3.5M |
| May 14, 2020 |
10-Q filing | 20.9M shares outstanding |
21M | 0 |
| Mar 30, 2020 |
8-K filing: Eton Pharmaceuticals, Inc. entered into a Securities Purchase Agreement with Opaleye L.P. to sell 2,000,000 shares of Common Stock for $3.00 per share and another agreement with certain investors to issue 600,000 shares of Common Stock also at $3.00 per share. ($7.8M proceeds) |
18M | 0 |
| Mar 05, 2020 |
10-K filing | 17.9M shares outstanding |
18M | 0 |